Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Sep. 2013,
MAKO Surgical received€0.28 Mil more from issuing new shares than it paid to buy back shares.
It received€0.00 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It received€1.32 Mil on other financial activities.
In all, MAKO Surgicalearned€1.59 Mil on financial activities for the
three
months ended in Sep. 2013.
MAKO Surgical Cash Flow from Financing Historical Data
The historical data trend for MAKO Surgical's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAKO Surgical Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
MAKO Surgical's Cash from Financing for the fiscal year that ended in Dec. 2012 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAKO Surgical (FRA:4M6) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
MAKO Surgical's issuance of stock for the
three
months ended in Sep. 2013 was €0.28 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
MAKO Surgical's repurchase of stock for the
three
months ended in Sep. 2013 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
MAKO Surgical's net issuance of debt for the
three
months ended in Sep. 2013 was €0.00 Mil.
MAKO Surgical received€0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
MAKO Surgical's net issuance of preferred for the
three
months ended in Sep. 2013 was €0.00 Mil.
MAKO Surgical paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
MAKO Surgical's cash flow for dividends for the
three
months ended in Sep. 2013 was €0.00 Mil.
MAKO Surgical received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
MAKO Surgical's other financing for the
three
months ended in Sep. 2013 was €1.32 Mil.
MAKO Surgical received€1.32 Mil on other financial activities.
MAKO Surgical Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of MAKO Surgical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
MAKO Surgical Corporation was incorporated in Delaware in November 2004. The Company is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. It offers MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient specific, osteoarthritic disease. The Company currently offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. MAKOplasty PKA, which requires extraction and replacement of the entire joint, enables resurfacing of one or two specific diseased compartments of the joint, preserving significantly more soft tissue and healthy bone of the knee. MAKOplasty procedures are enabled through its proprietary technology consisting of the components which includes its RIO system, its MAKOplasty applications, and its RESTORIS family of implant systems. The centerpiece of MAKOplasty is the RIO system, its proprietary robotic arm, interactive, orthopedic system, that provides both pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal and accurate implant insertion and alignment. The RIO system consists of two elements: a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The RIO system, version 2.0 of its Tactile Guidance System, or TGS, represents an important expansion from its first generation TGS, enabling and expanding the MAKOplasty PKA application to multicompartmental resurfacing procedures, allowing orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage, unicompartmental degeneration through mid-stage, multicompartmental degeneration with a modular knee implant system, as well as enabling the MAKOplasty THA application. The Company's MAKOplasty PKA application enables surgeons to isolate and resurface just one or two specific diseased compartments of the joint through a minimally invasive incision, preserving significantly more soft tissue and healthy bone of the knee. The MAKOplasty knee resurfacing procedure is performed by the surgeon using the surgical planning and execution software integrated into its patient specific visualization system. The Company's MAKOplasty THA application utilizes the RIO system's tactile, visual and auditory feedback to assist the surgeon in preparing the acetabulum (hip socket) for optimal placement of the acetabular cup implant. The MAKOplasty THA application allows the surgeon to preoperatively plan the placement of the hip implants on a three dimensional image of a pre-operative CT scan. Its RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint. Its RESTORIS family of knee implants for use in si
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:4M6 has been successfully added to your 